A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PDE5

Search Conditions:
Search Keyword : PDE5
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: PDE5
Appearance Frequency: 1485 time(s)
Long forms: 16

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
phosphodiesterase type 5
(1414 times)
Urology
(302 times)
ED (344 times)
NO (188 times)
cGMP (179 times)
1996 Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
phosphodiesterase type 5 inhibitors
(47 times)
Urology
(26 times)
ED (19 times)
IIEF (4 times)
AD (3 times)
2002 Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction.
phosphodiesterase isoform 5
(6 times)
Chemistry
(2 times)
ACE (1 time)
CVOD (1 time)
ED (1 time)
2006 Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance.
PDE type 5
(5 times)
Vascular Diseases
(2 times)
PDE (3 times)
AMP (1 time)
ANP (1 time)
2007 Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
phosphodiesterase inhibitor type 5
(2 times)
Reproductive Medicine
(1 time)
DRAQ (1 time)
ED (1 time)
iNO (1 time)
2013 Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?
1-(2-Ethoxyethyl)-1H-pyrazolo(4,3-d)pyrimidines as potent phosphodiesterase 5
(1 time)
Chemistry
(1 time)
--- 2010 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors.
Ambrisentan-Phosphodiesterase Type 5
(1 time)
Blood Circulation
(1 time)
ADR (1 time)
PAH (1 time)
2019 Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.
pain, erectile dysfunction, phosphodiesterase-5
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
SSRIs (1 time)
2005 Pharmacological treatment for premature ejaculation.
PDE isoenzyme 5
(1 time)
Chemistry
(1 time)
PDE (1 time)
2007 The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development.
10  PDE5-TG
(1 time)
Vascular Diseases
(1 time)
LV (1 time)
2009 Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
11  phosfodiesterasis-5
(1 time)
Gynecology
(1 time)
APA (1 time)
SD (1 time)
2009 [Sexual dysfunction in men after surgery of colorectal carcinoma. New developments in prevention and therapy].
12  Phosphodiesterase enzyme type 5
(1 time)
Psychopharmacology
(1 time)
AChE (1 time)
2005 Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation.
13  preclinical data demonstrating that phosphodiesterase-5
(1 time)
Neoplasms
(1 time)
HNSCC (1 time)
MDSC (1 time)
2014 Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
14  previously demonstrated that phosphodiesterase-5
(1 time)
Physiology
(1 time)
cGMP (1 time)
ET (1 time)
NO (1 time)
2014 Phosphodiesterase-5 activity exerts a coronary vasoconstrictor influence in awake swine that is mediated in part via an increase in endothelin production.
15  prostaglandin type-5
(1 time)
Urology
(1 time)
ED (1 time)
RP (1 time)
SNG (1 time)
2008 Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer.
16  protein expresion of phosphodiesterase5
(1 time)
Molecular Biology
(1 time)
AD (1 time)
NF-kappaB (1 time)
PPAR (1 time)
2016 Neuroprotective effects of sodium hydrosulfide against beta-amyloid-induced neurotoxicity.